Last Updated : March 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | ||
Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
Prevymis | letermovir | Cytomegalovirus infection (CMV), prophylaxis | Suspended | |||
Prevymis | letermovir | Cytomegalovirus infection, prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | ||
Prexige | Lumiracoxib | Osteoarthritis (Knee) | Do not list | Complete | ||
Prezcobix | Darunavir/cobicistat | HIV Infection | List with criteria/condition | Complete | ||
Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Prezista | Darunavir | HIV (treatment naive) | List with clinical criteria and/or conditions | Complete | ||
Prezista | Darunavir | HIV infection (Pediatric) | List with clinical criteria and/or conditions | Complete |